142 related articles for article (PubMed ID: 34354865)
1. A novel selective AKR1C3-activated prodrug AST-3424/OBI-3424 exhibits broad anti-tumor activity.
Meng F; Li WF; Jung D; Wang CC; Qi T; Shia CS; Hsu RY; Hsieh YC; Duan J
Am J Cancer Res; 2021; 11(7):3645-3659. PubMed ID: 34354865
[TBL] [Abstract][Full Text] [Related]
2. OBI-3424, a Novel AKR1C3-Activated Prodrug, Exhibits Potent Efficacy against Preclinical Models of T-ALL.
Evans K; Duan J; Pritchard T; Jones CD; McDermott L; Gu Z; Toscan CE; El-Zein N; Mayoh C; Erickson SW; Guo Y; Meng F; Jung D; Rathi KS; Roberts KG; Mullighan CG; Shia CS; Pearce T; Teicher BA; Smith MA; Lock RB
Clin Cancer Res; 2019 Jul; 25(14):4493-4503. PubMed ID: 31015346
[TBL] [Abstract][Full Text] [Related]
3. An AKR1C3-specific prodrug with potent anti-tumor activities against T-ALL.
Wang Y; Liu Y; Zhou C; Wang C; Zhang N; Cao D; Li Q; Wang Z
Leuk Lymphoma; 2020 Jul; 61(7):1660-1668. PubMed ID: 32091283
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of castration-resistant prostate cancer growth by genistein through suppression of AKR1C3.
Yu X; Yan J; Li Y; Cheng J; Zheng L; Fu T; Zhu Y
Food Nutr Res; 2023; 67():. PubMed ID: 36794010
[TBL] [Abstract][Full Text] [Related]
5. A Novel AKR1C3 Specific Prodrug TH3424 With Potent Antitumor Activity in Liver Cancer.
He P; Wang C; Wang Y; Wang C; Zhou C; Cao D; Li J; Bushnell DA; Li Q; Kornberg RD; Xie W; Wang Z
Clin Pharmacol Ther; 2021 Jul; 110(1):229-237. PubMed ID: 33483974
[TBL] [Abstract][Full Text] [Related]
6. The Activity of SN33638, an Inhibitor of AKR1C3, on Testosterone and 17β-Estradiol Production and Function in Castration-Resistant Prostate Cancer and ER-Positive Breast Cancer.
Yin YD; Fu M; Brooke DG; Heinrich DM; Denny WA; Jamieson SM
Front Oncol; 2014; 4():159. PubMed ID: 24995161
[TBL] [Abstract][Full Text] [Related]
7. Pre-clinical activity of PR-104 as monotherapy and in combination with sorafenib in hepatocellular carcinoma.
Abbattista MR; Jamieson SM; Gu Y; Nickel JE; Pullen SM; Patterson AV; Wilson WR; Guise CP
Cancer Biol Ther; 2015; 16(4):610-22. PubMed ID: 25869917
[TBL] [Abstract][Full Text] [Related]
8. Steroidogenic enzyme AKR1C3 is a novel androgen receptor-selective coactivator that promotes prostate cancer growth.
Yepuru M; Wu Z; Kulkarni A; Yin F; Barrett CM; Kim J; Steiner MS; Miller DD; Dalton JT; Narayanan R
Clin Cancer Res; 2013 Oct; 19(20):5613-25. PubMed ID: 23995860
[TBL] [Abstract][Full Text] [Related]
9. The bioreductive prodrug PR-104A is activated under aerobic conditions by human aldo-keto reductase 1C3.
Guise CP; Abbattista MR; Singleton RS; Holford SD; Connolly J; Dachs GU; Fox SB; Pollock R; Harvey J; Guilford P; Doñate F; Wilson WR; Patterson AV
Cancer Res; 2010 Feb; 70(4):1573-84. PubMed ID: 20145130
[TBL] [Abstract][Full Text] [Related]
10. Erratum: A novel selective AKR1C3-activated prodrug AST-3424/OBI-3424 exhibits broad anti-tumor activity.
Meng F; Li WF; Jung D; Wang CC; Qi T; Shia CS; Hsu RY; Hsieh YC; Duan J
Am J Cancer Res; 2023; 13(11):5750. PubMed ID: 38058837
[TBL] [Abstract][Full Text] [Related]
11. Characterization of AST-001 non-clinical pharmacokinetics: A novel selective AKR1C3-activated prodrug in mice, rats, and cynomolgus monkeys.
Meng T; Jung D; Cai XH; Lu ZQ; Yu JB; Qi TY; Meng FY; Ruan MZ; Duan JX
Biopharm Drug Dispos; 2024 Apr; 45(2):83-92. PubMed ID: 38492211
[TBL] [Abstract][Full Text] [Related]
12. AKR1C3 Inhibitor KV-37 Exhibits Antineoplastic Effects and Potentiates Enzalutamide in Combination Therapy in Prostate Adenocarcinoma Cells.
Verma K; Gupta N; Zang T; Wangtrakluldee P; Srivastava SK; Penning TM; Trippier PC
Mol Cancer Ther; 2018 Sep; 17(9):1833-1845. PubMed ID: 29891491
[TBL] [Abstract][Full Text] [Related]
13. Restoring Tumour Selectivity of the Bioreductive Prodrug PR-104 by Developing an Analogue Resistant to Aerobic Metabolism by Human Aldo-Keto Reductase 1C3.
Abbattista MR; Ashoorzadeh A; Guise CP; Mowday AM; Mittra R; Silva S; Hicks KO; Bull MR; Jackson-Patel V; Lin X; Prosser GA; Lambie NK; Dachs GU; Ackerley DF; Smaill JB; Patterson AV
Pharmaceuticals (Basel); 2021 Nov; 14(12):. PubMed ID: 34959631
[TBL] [Abstract][Full Text] [Related]
14. Mesoporous silica nanoparticles combined with AKR1C3 siRNA inhibited the growth of castration-resistant prostate cancer by suppressing androgen synthesis in vitro and in vivo.
Chen J; Yang Y; Xu D; Li J; Wu S; Jiang Y; Wang C; Yang Z; Zhao L
Biochem Biophys Res Commun; 2021 Feb; 540():83-89. PubMed ID: 33450484
[TBL] [Abstract][Full Text] [Related]
15. A Mansonone Derivative Coupled with Monoclonal Antibody 4D5-Modified Chitosan Inhibit AKR1C3 to Treat Castration-Resistant Prostate Cancer.
Zhou M; Wang X; Xia J; Cheng Y; Xiao L; Bei Y; Tang J; Huang Y; Xiang Q; Huang S
Int J Nanomedicine; 2020; 15():3087-3098. PubMed ID: 32431503
[TBL] [Abstract][Full Text] [Related]
16. A novel AKR1C3 specific prodrug AST-3424 and its combination therapy in hepatocellular carcinoma.
Xun C; Zhang Y; Zheng X; Qin S
J Pharmacol Sci; 2023 Jun; 152(2):69-75. PubMed ID: 37169481
[TBL] [Abstract][Full Text] [Related]
17. Rational design of an AKR1C3-resistant analog of PR-104 for enzyme-prodrug therapy.
Mowday AM; Ashoorzadeh A; Williams EM; Copp JN; Silva S; Bull MR; Abbattista MR; Anderson RF; Flanagan JU; Guise CP; Ackerley DF; Smaill JB; Patterson AV
Biochem Pharmacol; 2016 Sep; 116():176-87. PubMed ID: 27453434
[TBL] [Abstract][Full Text] [Related]
18. Interrogation of the Structure-Activity Relationship of a Lipophilic Nitroaromatic Prodrug Series Designed for Cancer Gene Therapy Applications.
Ashoorzadeh A; Mowday AM; Guise CP; Silva S; Bull MR; Abbattista MR; Copp JN; Williams EM; Ackerley DF; Patterson AV; Smaill JB
Pharmaceuticals (Basel); 2022 Feb; 15(2):. PubMed ID: 35215297
[TBL] [Abstract][Full Text] [Related]
19. Aldo-keto reductase family 1 member C3 (AKR1C3) is a biomarker and therapeutic target for castration-resistant prostate cancer.
Hamid AR; Pfeiffer MJ; Verhaegh GW; Schaafsma E; Brandt A; Sweep FC; Sedelaar JP; Schalken JA
Mol Med; 2013 Jan; 18(1):1449-55. PubMed ID: 23196782
[TBL] [Abstract][Full Text] [Related]
20. Hydroxytriazole derivatives as potent and selective aldo-keto reductase 1C3 (AKR1C3) inhibitors discovered by bioisosteric scaffold hopping approach.
Pippione AC; Giraudo A; Bonanni D; Carnovale IM; Marini E; Cena C; Costale A; Zonari D; Pors K; Sadiq M; Boschi D; Oliaro-Bosso S; Lolli ML
Eur J Med Chem; 2017 Oct; 139():936-946. PubMed ID: 28881288
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
